arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Xenetic Biosciences, Inc.

XBIO
$2.50 ▼ -0.06 (-2.15%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
62 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

Xenetic Biosciences, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $5.7M
Dividend Yield
Revenue Growth 12.0%
Op. Margin -147.1%
ROIC -12.6%
FCF / Share $-0.38
Trailing P/E
Price / Book 1.0x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

62-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$660.60K
↑ +12.0%
Net Income Profit after all expenses
$-929.70K
↓ -35.0%
Operating Margin Operating profit as % of sales
-147.1%
↓ -136.4% 2th
FCF / Share Free cash flow per share
$-0.38
↓ -63.0%
Long-Term Debt Long-term obligations
$212.81K
— 0.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
3
Returns
20
Cash Quality
57

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 15 years · 62 quarters